The European Commission has ruled that UCB’s anti-epileptic Vimpat can be used in children. More: EU allows use of UCB’s anti-epileptic Vimpat in children Source: News
read moreThe National Institute for Health and Care Excellence (NICE) has issued a final positive recommendation for Bayer’s Eylea as a treatment for adults for the treatment of visual impairment due to myopic chorodial neovascularisation. More: NICE nod for new Eylea
read moreSome patients with rheumatoid arthritis living in England and Wales should get ‘routine’ NHS access to Sanofi’s Kevzara after cost regulators issued draft guidelines deeming the drug cost effective. More: Sanofi’s Kevzara will be funded for NHS use Source: News
read moreUS regulators have issued a safety communication warning of the risk for serious liver injury and death from incorrect dosing of Intercept Pharmaceuticals’ Ocaliva in patients with primary biliary cholangitis. More: FDA warning on Intercept’s Ocaliva after patient deaths Source:
read morePfizer and Merck KGaA’s new immuno-oncology drug Bavencio, which won an FDA nod for Merkel cell carcinoma in March, is now approved in Europe to treat the aggressive type of skin cancer. More: Pfizer, Merck KGaA grab EU approval for
read moreThe breast cancer medication Ibrance has been the shooting star in Pfizer’s universe, and it’s expected to burn brightly enough to raise the entire company’s fortunes. Almost $5 billion bright in 2018, if one analyst’s predictions come true. More: Pfizer's
read more© 1994 - 2026 B.M. Pharmaceuticals